Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LYMPHVECs

Financiado

Cerrado

Development of lipid nanoparticles based on solid matrix for Benznidazole oral d...

Development of lipid nanoparticles based on solid matrix for Benznidazole oral delivery targeting to the lymphatic system to treat Chagas disease According to the WHO there are 8 million persons chronically infected by Chagas disease (CD) resulting in 12.000 reported deaths annually. CD is one of the most significant health problems of Latin America. However, nowadays it ha... ver más

31/03/2021

GLAXOSMITHKLINE IN...

158K€

Presupuesto del proyecto: 158K€

Líder del proyecto

GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO Investigacion y desarrollo de medicamentos entendiendo como tal el. conjunto de actividades consistentes en la investigacion cientifica

TRL 4-5 | 130K€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-03-31

MSCA-IF-2017: Individual Fellowships

I+D

Cerrada hace 7 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

GLAXOSMITHKLINE INVESTIGACIO...

158.12K€ | Lider

Proyectos interesantes

BERENICE

Medical Technol...

Nanotechnology

4M€ Cerrado

BIO2011-25039

Medical Technol...

Nanotechnology

224K€ Cerrado

MOTIF

Medical Technol...

Pharmaceutical...

8M€ Cerrado

pH4HIF

Medical Technol...

Pharmaceutical...

Cerrado

NanoGut

Medical Technol...

Nanotechnology

1M€ Cerrado

HormoCaps

Medical Technol...

Pharmaceutical...

150K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 35 meses Fecha Inicio: 2018-04-12
Fecha Fin: 2021-03-31

Líder del proyecto

GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO Investigacion y desarrollo de medicamentos entendiendo como tal el. conjunto de actividades consistentes en la investigacion cientifica

TRL 4-5 | 130K€

Presupuesto del proyecto 158K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto According to the WHO there are 8 million persons chronically infected by Chagas disease (CD) resulting in 12.000 reported deaths annually. CD is one of the most significant health problems of Latin America. However, nowadays it has been reported worldwide. Benznidazole (BZ) has been recently approved in US (30/08/2017) as the first option treatment for CD but can only administered for 14 days or less, while it is known that at least 2-3 months of treatment are required for full efficacy. This approval for short-term CD therapy is due to the severe side effects associated with extended use, which severely impacts the applicability of BZ as a universal CD treatment. Importantly, Trypanosoma cruzi (Tc) parasite reservoirs have been localized into the Lymphatic System (LS). Poor compound distribution into the LS could be the reason why extended BZ treatment is required and why reactivation of the parasites in the chronic stage is commonly found. Chagas infected people treated with BZ develop rashes, fever, nausea, headache, allergic dermatitis, digestive intolerance (anorexia), peripheral neuropathy and insomnia. These severe side effects limit its use and foster non-compliance. BZ formulations that reduce compound exposure in system circulation while facilitating distribution into the LS could reduce the efficacious dose (at present 5-7mg/kg/day), reduce side effects, and possibly contribute treatment shortening. This project will develop BZ formulations based on solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) to achieve these three goals.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores